A.R.M. Center for Otolaryngology Head and Neck Surgery, Assuta Medical Centers, Tel Aviv, Israel.
Ben-Gurion University of the Negev, Be'er Sheva, Israel.
Clin Endocrinol (Oxf). 2021 Jun;94(6):990-997. doi: 10.1111/cen.14415. Epub 2021 Jan 26.
Ultrasound (US) has gained a critical role in thyroid cancer treatment planning, yet it is limited by its user-dependent nature. The aim of this study was to compare the impact of US performed by radiologists specializing in thyroid imaging (hqUS) and US performed by radiographers in the community (cUS) on treatment plans of patients diagnosed with well-differentiated thyroid malignancies.
Retrospective single-centre case series with chart review.
Patients diagnosed with thyroid cancer during 2017-2019 that had cUS followed by hqUS pre-operative counselling were included in this retrospective analysis.
The main outcome was management alternations based on one of two sonographic measures: (1) extrathyroid extension (ETE); (2) The presence of central or lateral lymph nodes suspicious for metastases (LNM), which were compared with the final pathology.
Among those with non-recurrent tumour (n = 76), ETE was reported 22 times more by hqUS compared with cUS (28.9% vs 1.3%, P < .001). Central and lateral LNM were reported approximately 6.5 and 1.5 times more by hqUS, respectively (25.0% vs 3.9%, P < .001 and 15.8% vs., 9.2%, P = .227, respectively). Overall, hqUS altered the initial treatment plan of 35.5% of patients. In 27.6% of patients, hqUS and its subsequent surgery resulted in a change to the patients' 2015 ATA risk stratification system. In 40% of patients with microcarcinomas, hqUS findings mandated surgery according to findings that were not reported by cUS. False-positive rate was 5.2%.
Community US may under-diagnose important features such as ETE and LNM, leading to potential under-treatment in many patients. High-quality US of the neck should be considered in patients with differentiated thyroid carcinoma before making any treatment decisions.
超声(US)在甲状腺癌治疗计划中起着至关重要的作用,但它受到用户依赖性的限制。本研究的目的是比较由专门从事甲状腺成像的放射科医生(hqUS)进行的 US 和社区放射技师(cUS)进行的 US 对诊断为分化型甲状腺恶性肿瘤的患者的治疗计划的影响。
回顾性单中心病例系列,病历回顾。
本回顾性分析纳入了 2017 年至 2019 年间经 cUS 检查后行 hqUS 术前咨询诊断为甲状腺癌的患者。
主要结局是基于两种超声测量值之一的管理变化:(1)甲状腺外延伸(ETE);(2)中央或侧方淋巴结可疑转移(LNM)的存在,这些与最终病理结果进行比较。
在无复发性肿瘤患者中(n=76),hqUS 报告 ETE 的次数比 cUS 多 22 倍(28.9%比 1.3%,P<.001)。hqUS 报告中央和侧方 LNM 的次数分别约为 cUS 的 6.5 倍和 1.5 倍(25.0%比 3.9%,P<.001 和 15.8%比 9.2%,P=0.227)。总体而言,hqUS 改变了 35.5%患者的初始治疗计划。在 27.6%的患者中,hqUS 及其随后的手术改变了患者 2015 年 ATA 风险分层系统。在 40%的微癌患者中,hqUS 发现根据 cUS 未报告的发现需要手术。假阳性率为 5.2%。
社区 US 可能会漏诊 ETE 和 LNM 等重要特征,导致许多患者潜在的治疗不足。在做出任何治疗决策之前,应考虑对分化型甲状腺癌患者进行高质量的颈部超声检查。